TY - JOUR
T1 - Reducing the risk of venous thromboembolism following superficial endovenous treatment
T2 - A UK and Republic of Ireland consensus study
AU - Vascular and Endovascular Research Network (VERN) Collaborators
AU - Dattani, Nikesh
AU - Shalhoub, Joseph
AU - Nandhra, Sandip
AU - Lane, Tristan
AU - Abu-Own, Abdulsalam
AU - Elbasty, Ahmed
AU - Jones, Aled
AU - Garnham, Andrew
AU - Baig, Anzar
AU - Saratzis, Athanasios
AU - Sharif, Atif
AU - Huasen, Bella
AU - Dawkins, Claire
AU - Nesbitt, Craig
AU - Carradice, Daniel
AU - Morrow, Darren
AU - Bosanquet, David
AU - Kavanagh, Eamon
AU - Shaikh, Faisal
AU - Gosi, Gergely
AU - Ambler, Graeme
AU - Fulton, Gregory
AU - Singh, Gurdas
AU - Travers, Hannah
AU - Moore, Hayley
AU - Olivier, James
AU - Hitchman, Louise
AU - O'Donohoe, Martin
AU - Popplewell, Matthew
AU - Medani, Mekki
AU - Goh, Mingzheng A
AU - Lyons, Oliver
AU - McBride, Olivia
AU - Moxey, Paul
AU - Stather, Philip
AU - Burns, Phillipa
AU - Forsythe, Rachel
AU - Sam, Rachel
AU - Brar, Ranjeet
AU - Brightwell, Robert
AU - Benson, Ruth
AU - Onida, Sarah
AU - Paravastu, Sharath
AU - Lambracos, Simon
AU - Vallabhaneni, Srinivasa R
AU - Walsh, Stewart
AU - Aktar, Tasleem
AU - Moloney, Tony
AU - Mzimba, Zola
AU - Nyamekye, Isaac
N1 - The acceptance date for this record is provisional and based upon the month of publication for the article.
PY - 2020/7/1
Y1 - 2020/7/1
N2 - OBJECTIVES: Venous thromboembolism is a potentially fatal complication of superficial endovenous treatment. Proper risk assessment and thromboprophylaxis could mitigate this hazard; however, there are currently no evidence-based or consensus guidelines. This study surveyed UK and Republic of Ireland vascular consultants to determine areas of consensus.METHODS: A 32-item survey was sent to vascular consultants via the Vascular and Endovascular Research Network (phase 1). These results generated 10 consensus statements which were redistributed (phase 2). 'Good' and 'very good' consensus were defined as endorsement/rejection of statements by >67% and >85% of respondents, respectively.RESULTS: Forty-two consultants completed phase 1. This generated seven statements regarding risk factors mandating peri-procedural pharmacoprophylaxis and three statements regarding specific pharmacoprophylaxis regimes. Forty-seven consultants completed phase 2. Regarding venous thromboembolism risk factors mandating pharmacoprophylaxis, 'good' and 'very good' consensus was achieved for 5/7 and 2/7 statements, respectively. Regarding specific regimens, 'very good' consensus was achieved for 3/3 statements.CONCLUSIONS: The main findings from this study were that there was 'good' or 'very good' consensus that patients with any of the seven surveyed risk factors should be given pharmacoprophylaxis with low-molecular-weight heparin. High-risk patients should receive one to two weeks of pharmacoprophylaxis rather than a single dose.
AB - OBJECTIVES: Venous thromboembolism is a potentially fatal complication of superficial endovenous treatment. Proper risk assessment and thromboprophylaxis could mitigate this hazard; however, there are currently no evidence-based or consensus guidelines. This study surveyed UK and Republic of Ireland vascular consultants to determine areas of consensus.METHODS: A 32-item survey was sent to vascular consultants via the Vascular and Endovascular Research Network (phase 1). These results generated 10 consensus statements which were redistributed (phase 2). 'Good' and 'very good' consensus were defined as endorsement/rejection of statements by >67% and >85% of respondents, respectively.RESULTS: Forty-two consultants completed phase 1. This generated seven statements regarding risk factors mandating peri-procedural pharmacoprophylaxis and three statements regarding specific pharmacoprophylaxis regimes. Forty-seven consultants completed phase 2. Regarding venous thromboembolism risk factors mandating pharmacoprophylaxis, 'good' and 'very good' consensus was achieved for 5/7 and 2/7 statements, respectively. Regarding specific regimens, 'very good' consensus was achieved for 3/3 statements.CONCLUSIONS: The main findings from this study were that there was 'good' or 'very good' consensus that patients with any of the seven surveyed risk factors should be given pharmacoprophylaxis with low-molecular-weight heparin. High-risk patients should receive one to two weeks of pharmacoprophylaxis rather than a single dose.
KW - Deep vein thrombosis
KW - varicose veins
KW - venous thromboembolism
KW - VTE management
UR - http://dx.doi.org/10.1177/0268355520936420
U2 - 10.1177/0268355520936420
DO - 10.1177/0268355520936420
M3 - Article (Academic Journal)
C2 - 32611228
SN - 0268-3555
VL - 35
SP - 706
EP - 714
JO - Phlebology
JF - Phlebology
IS - 9
ER -